Innovative Low-Toxicity Cancer Therapy Unveiled

This chapter investigates D-hematoxilin's role in selectively disrupting protein kinase CK2 function in cancer cells, presenting it as a promising adjunct to chemotherapy. The discussion emphasizes the need for meticulous clinical trials to validate its efficacy and safety, especially in challenging cancers like blood malignancies.